Rising Prevalence of Infectious Diseases Will Propel Growth
A molecular diagnostic is an effective tool for the detection of HIV, HPV, and other infectious diseases. The increasing demand for molecular diagnostics is likely to boost the global infectious disease molecular diagnostics market revenue during the forecast period. Government support to tackle the rising cases of infectious diseases is predicted to further augment the growth of the global infectious disease molecular diagnostics market. The acquisitions and collaborations between key companies are also expected to contribute positively to the global infectious disease molecular diagnostics growth.
Browse Complete Report Details @ https://www.fortunebusinessinsights.com/industry-reports/infectious-disease-molecular-diagnostics-market-101146
For instance, Bruker Corporation announced the acquisition of Hain Lifescience GmbH, an infectious disease molecular diagnostics company, to expand its footprint in molecular diagnostics. The launch of new molecular diagnostics platforms or instruments is likely to enable growth of the global infectious disease molecular diagnostics market. For instance, Qiagen announced the launch of QIAscreen HPV PCR Test, an in-vitro molecular diagnostics test for the detection of human papillomavirus in Europe.
The increasing incidence of infectious diseases around the world is driving the global infectious disease molecular diagnostics market, says Fortune Business Insights, in a report, titled “Infectious Disease Molecular Diagnostics Market Size, Share and Global Trend By Technology (Mass Spectroscopy, Capillary Electrophoresis, Next Generation Sequencing, Chips and Microarrays, In-Situ Hybridization), By Disease Indication (Hepatitis, Human Immunodeficiency Virus (HIV) Infection, Human Papillomavirus (HPV) Infection), By End User (Hospitals and Clinics, Diagnostic Centres, Research Institutes) and Geography Forecast till 2026.” Rising awareness regarding prevention and early diagnosis of sexually transmitted diseases is expected to aid the growth of the global infectious disease molecular diagnostics market.
- Mass Spectroscopy
- Capillary Electrophoresis
- Next Generation Sequencing (NGS)
- Chips and Microarrays
- In-Situ Hybridization (ISH)
By Disease Indication
- Human Immunodeficiency Virus (HIV) Infection
- Human Papillomavirus (HPV) Infection
By End User
- Hospitals and Clinics
- Diagnostic Centres
- Research Institutes
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
Active Government Support Will Aid Growth in the Asia Pacific
Geographically, the global infectious disease molecular diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is expected to dominate the global infectious disease molecular diagnostics market during the forecast period owing to the increasing prevalence of infectious diseases such as HIV and respiratory diseases. Established healthcare system and increasing RandD investment is also expected to enable the growth of the global infectious disease molecular diagnostics market.
Some of the major companies that are present in the global infectious disease molecular diagnostics market are Abbott, Becton, Dickinson and Company, QIAGEN, Cepheid, bioMérieux SA, Hologic Inc., Myriad Genetics and Thermo Fisher Scientific.
Some of the Main Key Players Covered in the Report:
- Dickinson and Company
- bioMérieux SA
- Hologic Inc.
- Myriad Genetics
- Thermo Fisher Scientific
More Trending Topics from Fortune Business Insights: